Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Accumulated Expenses (2023 - 2026)

Alto Neuroscience has reported Accumulated Expenses over the past 4 years, most recently at $7.6 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $7.6 million for Q1 2026, up 29.58% from a year ago — trailing twelve months through Mar 2026 was $7.6 million (up 29.58% YoY), and the annual figure for FY2025 was $8.9 million, up 5.14%.
  • Accumulated Expenses reached $7.6 million in Q1 2026 per ANRO's latest filing, down from $8.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.9 million in Q4 2025 and bottomed at $4.4 million in Q1 2024.
  • Median Accumulated Expenses over the past 4 years was $6.7 million (2025), compared with a mean of $6.7 million.
  • The largest annual shift saw Accumulated Expenses surged 85.82% in 2024 before it dropped 15.16% in 2025.
  • Over 4 years, Accumulated Expenses stood at $4.5 million in 2023, then skyrocketed by 85.82% to $8.4 million in 2024, then grew by 5.14% to $8.9 million in 2025, then decreased by 14.13% to $7.6 million in 2026.
  • Business Quant data shows Accumulated Expenses for ANRO at $7.6 million in Q1 2026, $8.9 million in Q4 2025, and $7.0 million in Q3 2025.